Zacks Investment Research on MSN3h
LLY vs. NVO: Which Weight-Loss Drug Stock is a Stronger Play Now?
Novo Nordisk NVO and Eli Lilly LLY dominate the diabetes and obesity market on the back of the tremendous success of their ...
BT Exclusive: Novo Nordisk to launch Wegovy in India this year, confirms India MD
Obesity drug market heats up in India; Novo Nordisk advances Wegovy launch from 2026 to coming months to challenge Eli ...
The Print8h
Big buzz over Mounjaro launch but here’s why India’s anti-obesity drug market may only take off next yr
India’s obesity crisis fuels a $2.6 bn drug race as pharma firms rush to launch affordable semaglutide generics, aiming to ...
Canadian scientist wins Breakthrough Prize for discovery of hormone used in Ozempic, Mounjaro
Dr. Daniel Drucker, an endocrinologist and a clinician-scientist at the University of Toronto and the Lunenfeld-Tanenbaum ...
Medicare Will Not Cover GLP-1 Drugs for Weight Loss
The decision counters a proposal by the Biden Administration to reimburse beneficiaries for the weight-loss medications.